Chemomab Therapeutics (CMMB) Operating Expenses (2017 - 2025)

Chemomab Therapeutics' Operating Expenses history runs 9 years deep, the most recent figure standing at $2.0 million for Q4 2025.

• Quarterly Operating Expenses fell 38.56% year-over-year to $2.0 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $9.6 million (down 35.09% YoY) and the FY2025 annual result came in at $9.6 million, down 35.09% from the prior year.
• Operating Expenses was $2.0 million for Q4 2025 at Chemomab Therapeutics, up from $1.8 million in the prior quarter.
• Across five years, Operating Expenses topped out at $9.0 million in Q1 2023 and bottomed at $1.7 million in Q1 2021.
• A 5-year average of $4.5 million and a median of $3.8 million in 2023 frame the typical range for Operating Expenses.
• Annual changes were most pronounced in 2022 — Operating Expenses soared 213.13% — and 2023, when it tumbled 55.47%.
• Chemomab Therapeutics' Operating Expenses stood at $5.0 million in 2021, then jumped by 72.01% to $8.6 million in 2022, then sank by 55.47% to $3.8 million in 2023, then decreased by 16.5% to $3.2 million in 2024, then plunged by 38.56% to $2.0 million in 2025.
• Business Quant data shows CMMB's Operating Expenses at $2.0 million in Q4 2025, $1.8 million in Q3 2025, and $2.3 million in Q2 2025.